Advanced Chemistry Development, Inc., and Chenomx, Inc., Announce Metabolic Profiling Software Integration
Buena Vista, FL, December 13, 2004 -
Advanced Chemistry Development, Inc., (ACD/Labs) and Chenomx, Inc., (Chenomx) are pleased to announce that with the release of version 3.1, Chenomx's Eclipse Metabolic Profiling software will support NMR spectra prepared using ACD/Labs' 1D NMR Processor. This development is in response to requests from an evolving and increasingly savvy Metabolic Profiling industry that requires new ways to ensure careful preparation of the spectra used in metabolic studies.
Chenomx Eclipse software offers the user the ability to completely deconvolute a Biofluid spectrum into the individual components and their quantities. These quantities are only available if the spectrum has been carefully prepared. Unfortunately preparation of the NMR spectra of biofluids can be particularly challenging. The presence of high concentrations of salt water as a solvent, and often low sample sizes combine to create special challenges for the production of the spectrum as well as the subsequent processing and analysis of it.
ACD/Labs has been in the business of processing NMR spectra for many years, and is considered the industry standard in baseline and phase correction. Chenomx users now have the option of preparing their spectra with ACD/Labs' NMR processing tools, ensuring that their biofluid spectra are prepared using the highest standards.
Brent Lefebvre, NMR Product Manager for ACD/Labs, commented on the integration, "User's can now employ ACD/Labs' unmatched automatic processing capability before the complete mixture deconvolution that is possible in Chenomx Eclipse. This gives our users the best of both worlds by allowing them to utilize both software packages in a single process which exploits the core competency of each for a maximum benefit."
Chris Erasmus, Marketing Manager for Chenomx, says, "Chenomx recognizes the substantial number of users of ACD/Lab's software and has developed this information-rich solution as an added value service."
The system will be unveiled on Monday, December 13, 2004, at the CHI Conference on Metabolic Profiling in Buena Vista, Florida.
About Advanced Chemistry Development, Inc.
Advanced Chemistry Development, Inc., (ACD/Labs) is a chemistry software company offering solutions that truly integrate chemical structures with analytical chemistry information. ACD/Labs creates innovative software packages that aid chemical research scientists worldwide with spectroscopic validation of structures, elucidation of unknown substances, chromatographic separation, medicinal chemistry, preformulation of novel drug agents, and chemical patenting and publication. Combined, ACD/Labs solutions create an analytical informatics system that provides dramatic feed-forward effects on the chemical research process. Founded in 1993, and headquartered in Toronto, Canada, ACD/Labs employs a team of over 100 dedicated individuals whose continual efforts carry ACD/Labs innovative technologies into pharmaceutical, biotech, chemical, and materials companies throughout the world. Information about Advanced Chemistry Development and its products can be found at www.acdlabs.com.
About Chenomx, Inc.
Chenomx, Inc. is a privately-held Canadian company that specializes in the development of complex mixture analysis software for broad application in life science technologies. With world-class expertise in NMR spectroscopy, pharmaceutical sciences, and computer software, Chenomx leads the metabolic profiling field with its revolutionary Eclipse software. More information on Chenomx and its solutions is available at www.chenomx.com.
|
